As #AS­CO19 looms, a top an­a­lyst show­ers some love — and block­buster sta­tus — on Am­gen's KRAS killer

Am­gen is feel­ing the love this morn­ing.

Ge­of­frey Porges, a top biotech an­a­lyst at SVB Leerink known for his hard-hit­ting style, is putting the spot­light on their KRAS drug AMG510, pro­ject­ing a peak sales po­ten­tial of $2.3 bil­lion while ad­vis­ing Am­gen to keep this one for the home team.

With AS­CO loom­ing this week­end, there’s been a grow­ing fo­cus on KRAS, one of the tough­est tar­gets in on­col­o­gy R&D. Am­gen is a leader among a group of de­vel­op­ers who have found a toe­hold on KRAS: G12C. And Porges be­lieves that Am­gen has a rea­son­able shot at mak­ing a drug that can con­ceiv­ably work in lung, col­orec­tal, pan­cre­at­ic, and uter­ine can­cer — which qual­i­fies as a po­ten­tial mar­ket mas­ter worth bil­lions in sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER